Innodata Inc vs McKesson Corporation — how do they compare? Innodata Inc trades at $62.81 (market cap $2.03B), while McKesson Corporation trades at $823.64 (market cap $97.35B). The key difference: McKesson Corporation is far larger — about 48× Innodata Inc's market cap, and McKesson Corporation pays a 0.39% dividend while Innodata Inc pays none. Which is the better fit depends on your goals.
| INOD | MCK | |
|---|---|---|
Market Cap | $2.03B | $97.35B |
Sector | Technology | Health |
52-Week High | $121.50 | $995.69 |
52-Week Low | $34.45 | $659.01 |
Enterprise Value | $1.91B | $101.98B |
Dividend Yield | — | 0.39% |
Signals from Pluang's Aura AI — not financial advice
INOD trades at $62.08, up 2.09% today, showing strong momentum despite a bearish technical signal. The company demonstrates robust fundamentals with revenue growth from $252M in 2025 to $283M projected for 2026, and net income margins improving to 13.86%. Recent earnings beats and positive AI-driven news highlight growing demand for its engineering R&D services. Technical indicators show mixed signals with RSI suggesting oversold conditions but moving averages indicating bearish pressure.
Outlook remains positive with 60% analyst buy ratings and a $130 consensus price target representing 109% upside. Key opportunities include AI market expansion and customer diversification, while risks center on high valuation multiples (P/E 54.29) and customer concentration. The stock's recent 33% pullback may present a buying opportunity for growth-oriented investors.
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
Trailing returns across standard periods
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →